Results 161 to 170 of about 2,173,693 (307)

Long‐Acting Therapeutics in Pediatric Health: Bridging Innovation and Access

Clinical Pharmacology &Therapeutics, EarlyView.
Children have distinct therapeutic needs arising from age‐dependent physiology, disease epidemiology, formulation requirements, dosing considerations, and safety vulnerabilities. Despite substantial reductions in childhood mortality over the past three decades, nearly 5 million children under five died in 2023, with infectious diseases continuing to ...
Prajith Venkatasubramanian, Moherndran Archary, Daniel B. Hawcutt, Rachel Daley, Edmund Capparelli, Adeniyi Olagunju   +5 more
wiley   +1 more source

Monitoring the Performance of National Immunization Programs: Innovative Methodology and Tool for Countries' Self-Assessment. [PDF]

Vaccines (Basel)
Loayza S, Capistrán B, Contreras M, Velandia M, Salas D.   +4 more
europepmc   +1 more source

Recent changes to adult national immunization programs for pneumococcal vaccination in Europe and how they impact coverage: A systematic review of published and grey literature. [PDF]

Hum Vaccin Immunother, 2023
Arya S, Norton N, Kaushik P, Brandtmüller A, Tsoumani E.   +4 more
europepmc   +1 more source

Phase I Evaluation of Siltartoxatug, a First‐in‐Class Anti‐Tetanus Monoclonal Antibody: Safety, Pharmacokinetics and Pharmacodynamics in Healthy Australian and Chinese Populations

Clinical Pharmacology &Therapeutics, EarlyView.
Siltartoxatug, a first‐in‐class monoclonal antibody targeting tetanus toxin for post‐exposure prophylaxis, was evaluated in two phase I trials in Australian and Chinese healthy adults. In these randomized, double‐blind, placebo‐controlled, dose‐escalation studies, participants received a single intramuscular injection of siltartoxatug (10–250 μg/kg) or
Xinyu Liu, Zhigang Liu, Xiaohu Kuang, Yueming Wang, Xiaoyi Liu, Jiyuan Ding, Xia Zhou, Xin Zhou, Qianyu Liang, Meizhuo Zhang, Hao Zhao, Qingqing Tan, Weihong Zheng, Huaxin Liao, Charlotte Lemech, Wanmei Wang   +15 more
wiley   +1 more source

Evaluating Vaccination Coverage and Willingness to Participate in Immunization Programs Among People Living in Prison: A Cross-Sectional Survey in Italy. [PDF]

Vaccines (Basel)
Paduano G, Sansone V, Aiello V, Di Giuseppe G, Pavia M.   +4 more
europepmc   +1 more source

Establishment of pediatric reference ranges for circulating naïve and memory T and B cell subsets guided by the human immunophenotyping consortium standardization initiative: A large, single center U.S. experience

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Our knowledge of the immune system continues to expand at a rapid pace, and this coupled with technological advances now enables us to interrogate both the breadth and the depth of the immune response at levels without precedent. This has also facilitated rapidly integrating some of this carefully vetted knowledge into clinical practice ...
Aaruni Khanolkar, Aisha Ahmed
wiley   +1 more source

Recovery of child immunization programs post COVID-19

Asian Pacific Journal of Tropical Medicine, 2021
Giao Huynh, Han Thi Ngoc Nguyen, An Le Pham   +2 more
doaj   +1 more source

Correction: Loayza et al. Monitoring the Performance of National Immunization Programs: Innovative Methodology and Tool for Countries' Self-Assessment. <i>Vaccines</i> 2026, <i>14</i>, 258. [PDF]

Vaccines (Basel)
Loayza S, Capistrán B, Contreras M, Velandia M, Salas D.   +4 more
europepmc   +1 more source

Country score tool to assess readiness and guide evidence generation of immunization programs in aging adults in Europe. [PDF]

Front Public Health, 2022
Pham TH, Beck E, Postma MJ, Németh B, Ágh T, de Waure C, Salisbury DM, Nutma N, van der Schans J.   +8 more
europepmc   +1 more source

Engineering mRNA‐LNP Medicines for the Ageing Brain: Opportunities and Challenges for Neurodegenerative Diseases

Exploration, EarlyView.
This review highlights recent advances in engineering messenger RNA (mRNA)‐lipid nanoparticles (LNPs) to cross the ageing blood–brain barrier and target neurodegenerative diseases. It outlines design principles, delivery routes, and translational challenges, charting a roadmap towards clinical application of mRNA‐LNP therapeutics for neurodegenerative ...
Abdel Ali Belaidi, Denzil L. Furtado, Francesca Alves, Rebecca M. Nisbet, Scott Ayton, Ashley I. Bush   +5 more
wiley   +1 more source